Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Purple Biotech Ltd. Sponsored ADR (PPBT : NSDQ)

• Company Description    Purple Biotech Ltd. is a clinical-stage company focusing on therapies to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. Purple Biotech Ltd., formerly known as Kitov Pharma Ltd., is based in TEL AVIV, Israel. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $2.35 Daily Weekly Monthly 20 Day Moving Average: 24,410 shares Shares Outstanding: 1.33 (millions) Market Capitalization: $3.12 (millions) Beta: 0.41 52 Week High: $10.20 52 Week Low: $2.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.50% -16.29% 12 Week -5.82% -23.17% Year To Date -50.00% -52.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4 OPPENHEIMER STREET SCIENCE PARK - REHOVOT,L3 7670104 ISR ph: 972-3933-3121 fax: 972-3509-7196 ir@purple-biotech.com http://www.purple-biotech.com

• General Corporate Information    Officers Gil Efron - Chief Executive Officer and Acting Chief Financial Eric Rowinsky - Chairman and Director Isaac Israel - Director Simcha Rock - Director Ido Agmon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74638P208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/15/25 Share - Related Items Shares Outstanding: 1.33 Most Recent Split Date: 9.00 (0.05:1) Beta: 0.41 Market Capitalization: $3.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 94.69% vs. Previous Quarter: 34.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -17.84 12/31/24 - -30.83 ROA 06/30/25 - - 03/31/25 - -15.44 12/31/24 - -25.57 Current Ratio 06/30/25 - - 03/31/25 - 2.72 12/31/24 - 2.23 Quick Ratio 06/30/25 - - 03/31/25 - 2.72 12/31/24 - 2.23 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 24.58 12/31/24 - 24.74 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©